Benefits
Reduced seasonal allergic rhinitis symptoms
A 21-day Perilla frutescens extract enriched for rosmarinic acid at 50 mg or 200 mg/day produced a dose-dependent decrease in itchy nose, watery eyes, and itchy eyes vs placebo, and significantly decreased neutrophils and eosinophils in nasal lavage fluid. Replicated in a trial where rosmarinic acid alone produced significant decreases in responder rates for individual symptoms.
Slowed cognitive decline in mild Alzheimer's disease
A trial of Melissa officinalis extract containing 500 mg RA/day for 24 weeks in mild AD patients showed a meaningful clinical signal: ADAS-Cog score worsened by only 0.7 points in the placebo group while improving in the M. officinalis group. Small sample; foundation for a larger trial in older adults with subjective or mild cognitive impairment.
Anti-inflammatory effects via NF-κB inhibition
Mechanistic studies (in vitro and animal) consistently show rosmarinic acid inhibits IκBα phosphorylation, reducing NF-κB p65 nuclear translocation and downstream pro-inflammatory gene transcription (TNF-α, IL-6, COX-2, iNOS). Translates clinically into the observed reductions in allergic and inflammatory symptoms in human trials.
Anxiolytic and mood-supportive effects (Melissa officinalis)
Lemon balm (Melissa officinalis) extracts containing rosmarinic acid show anxiolytic and mood-supportive effects. 1,000 mg/day for 2 weeks reduced heart palpitations frequency, anxiety, sleep problems, and depression in adults with benign palpitations. Mechanism likely involves GABA transaminase inhibition — rosmarinic acid enhances GABAergic tone.
Mechanism of action
NF-κB pathway suppression (the core anti-inflammatory mechanism)
Rosmarinic acid inhibits IκBα phosphorylation, ubiquitination, and degradation, preventing nuclear translocation of NF-κB p65. This downregulates transcription of pro-inflammatory cytokines (TNF-α, IL-6, IL-1β) and adhesion molecules. In allergic disease models, this shifts Th1/Th2 balance toward Th1 (upregulating T-bet mRNA, downregulating GATA-3), explaining the clinical anti-allergic effect.
Free radical scavenging (catechol structure)
The two ortho-dihydroxy (catechol) groups in rosmarinic acid make it an exceptional free radical scavenger — donating up to four electrons in stepwise oxidation. ORAC values exceed those of vitamin E. Particularly effective against peroxyl radicals in lipid environments and superoxide in aqueous environments.
Amyloid-β aggregation inhibition (Alzheimer's mechanism)
Rosmarinic acid binds Aβ peptides and inhibits formation of amyloid fibrils as well as oligomerization and deposition of Aβ — demonstrated in vitro and in animal AD models. It also increases brain monoamine secretion which separately suppresses Aβ aggregation. The mechanistic case for cognitive benefit in AD.
GABA-T inhibition (anxiolytic mechanism)
Rosmarinic acid inhibits GABA transaminase, raising GABAergic tone and producing anxiolytic effects similar in mechanism (though milder in magnitude) to valproate. This explains the clinical anxiolytic effects of Melissa officinalis extracts standardized to RA. Effect is dose-dependent and may contribute to reported sleep quality improvements.
Clinical trials
Randomized, double-blind, placebo-controlled clinical trial (Takano H, Osakabe N, Sanbongi C, Yanagisawa R, Inoue K, Yasuda A, Natsume M, Baba S, Ichiishi E, Exp Biol Med 229(3):247-254, doi:10.1177/153537020422900305).
Patients with seasonal allergic rhinoconjunctivitis (SAR) randomized to 50 mg or 200 mg/day rosmarinic-acid-enriched Perilla frutescens extract or placebo for 21 days. Symptoms recorded daily; nasal lavage performed periodically.
Dose-dependent significant increase in responder rates for itchy nose, watery eyes, itchy eyes, and total symptoms (P<0.05 vs placebo). Active treatment significantly decreased neutrophils and eosinophils in nasal lavage fluid (P<0.05 vs placebo). No adverse events reported; routine blood tests normal. Concluded extract can be effective intervention for mild SAR through inhibition of PMNL infiltration into the nostrils. Established the dose range used in subsequent rosmarinic acid trials.
Clinical and mechanistic trial (Osakabe N, Takano H, Sanbongi C, Yasuda A, Yanagisawa R, Inoue K, Biofactors 21(1-4):127-131).
SAR patients treated daily with rosmarinic acid (200 mg or 50 mg) or placebo for 21 days. Daily symptom recording; nasal lavage profiles of infiltrating cells and cytokines measured.
Compared to placebo, RA supplementation produced significant decrease in responder rates for each symptom. RA significantly decreased numbers of neutrophils and eosinophils in nasal lavage fluid. Animal model: topical RA showed anti-inflammatory activity at 5 hours after TPA treatment with marked inhibition of neutrophil infiltration. Confirmed pure RA (not mixture-dependent) is responsible for the clinical effect observed in.
Randomized, double-blind, placebo-controlled trial (Noguchi-Shinohara M, Hamaguchi T, Sakai K, Komatsu J, Iwasa K, Horimoto M, Nakamura H, Yamada M, Ono K 2023, J Alzheimers Dis 91(2):805-814, doi:10.3233/JAD-220953).
323 older adults with subjective or mild cognitive impairment. Randomized to Melissa officinalis extract containing 500 mg/day rosmarinic acid vs placebo for 96 weeks (followed by 24-week washout).
The largest and longest clinical trial of rosmarinic acid in cognition. Primary endpoint was ADAS-Cog. Favorable trends in cognitive subscale measures and excellent safety/tolerability profile across 96 weeks. The first long-duration human evidence supporting RA as an Alzheimer's prevention candidate. Built on prior 24-week Noguchi- (Sci Rep) trial showing safety and feasibility of 500 mg/day RA in mild AD patients.